Search research articles
Contact Us
Filters
Showing results (51-60 of 459) with videos related to
Page
of 46
Sort By:
Frontiers in Oncology
|
May 21, 2019
Editorial: Emerging Biomarkers in Genitourinary Tumors
Rodolfo Montironi, Matteo Santoni, Alessia Cimadamore, et al.
Medical Sciences (Basel, Switzerland)
|
December 6, 2019
Transient Receptor Potential Cation Channels in Cancer Therapy
Giorgio Santoni, Federica Maggi, Maria Beatrice Morelli, et al.
Seminars in Cancer Biology
|
September 18, 2021
Microbiota and prostate cancer
Alessandro Rizzo, Matteo Santoni, Veronica Mollica, et al.
Cancer Treatment Reviews
|
June 17, 2016
Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges
Francesca Tartari, Matteo Santoni, Luciano Burattini, et al.
European Urology
|
February 7, 2021
Re: Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy
Matteo Santoni, Francesco Massari, Giorgio Santoni, et al.
Expert Opinion on Biological Therapy
|
June 20, 2024
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?
Matteo Rosellini, Andrea Marchetti, Elisa Tassinari, et al.
Expert Review of Anticancer Therapy
|
August 27, 2021
Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence
Matteo Santoni, Roberto Iacovelli, Valentina Colonna, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer
|
October 14, 2022
MiT translocation renal cell carcinoma: A review of the literature from molecular characterization to clinical management
Mimma Rizzo, Gaetano Pezzicoli, Matteo Santoni, et al.
European Urology
|
July 29, 2015
Re: Johan Lindberg, Anna Kristiansen, Peter Wiklund, Henrik Grönberg, Lars Egevad. Tracking the Origin of Metastatic Prostate Cancer. Eur Urol 2015;67:819-22
Francesco Piva, Matteo Santoni, Marina Scarpelli, et al.
Future Oncology (London, England)
|
December 20, 2021
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, et al.
Page
of 46
Search research articles
Search
Showing results (51-60 of 459) with videos related to
Sort By:
Page
of 46
Frontiers in Oncology
|
May 21, 2019
Editorial: Emerging Biomarkers in Genitourinary Tumors
Rodolfo Montironi, Matteo Santoni, Alessia Cimadamore, et al.
Medical Sciences (Basel, Switzerland)
|
December 6, 2019
Transient Receptor Potential Cation Channels in Cancer Therapy
Giorgio Santoni, Federica Maggi, Maria Beatrice Morelli, et al.
Seminars in Cancer Biology
|
September 18, 2021
Microbiota and prostate cancer
Alessandro Rizzo, Matteo Santoni, Veronica Mollica, et al.
Cancer Treatment Reviews
|
June 17, 2016
Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges
Francesca Tartari, Matteo Santoni, Luciano Burattini, et al.
European Urology
|
February 7, 2021
Re: Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy
Matteo Santoni, Francesco Massari, Giorgio Santoni, et al.
Expert Opinion on Biological Therapy
|
June 20, 2024
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?
Matteo Rosellini, Andrea Marchetti, Elisa Tassinari, et al.
Expert Review of Anticancer Therapy
|
August 27, 2021
Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence
Matteo Santoni, Roberto Iacovelli, Valentina Colonna, et al.
Biochimica Et Biophysica Acta. Reviews on Cancer
|
October 14, 2022
MiT translocation renal cell carcinoma: A review of the literature from molecular characterization to clinical management
Mimma Rizzo, Gaetano Pezzicoli, Matteo Santoni, et al.
European Urology
|
July 29, 2015
Re: Johan Lindberg, Anna Kristiansen, Peter Wiklund, Henrik Grönberg, Lars Egevad. Tracking the Origin of Metastatic Prostate Cancer. Eur Urol 2015;67:819-22
Francesco Piva, Matteo Santoni, Marina Scarpelli, et al.
Future Oncology (London, England)
|
December 20, 2021
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials
Alessandro Rizzo, Veronica Mollica, Matteo Santoni, et al.
Page
of 46